Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

Experimental Hematology & Oncology

Paraic A Kenny²  Joseph A Sparano⁴  Lisa Wiechmann¹  Shabana Shabbeer²  Eirini Pectasides³  Esther A Peterson² 

[1] Departments of Surgery, Albert Einstein College of Medicine, Bronx, NY 10461, USA;Departments of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA;Montefiore Medical Center, Bronx, NY 10461, USA;Departments of Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

关键词: Epidermal growth factor receptor;    Amphiregulin;    Serum biomarker;    Breast cancer;   

Others  :  812053
DOI  :  10.1186/2162-3619-2-25

 received in 2013-08-19, accepted in 2013-09-05,  发布年份 2013

【 摘 要 】

Background

Expression of the Epidermal Growth Factor Receptor ligand, Amphiregulin, has been associated with estrogen receptor positive breast cancer. As Amphiregulin is proteolytically released from the surface of breast cancer cells, we investigated the levels of Amphiregulin in the serum of breast cancer patients and cancer-free women to evaluate its potential utility as a breast cancer biomarker.

Findings

Serum Amphiregulin levels were quantified by ELISA from 125 cancer-free women and 114 breast cancer patients. No significant association between serum Amphiregulin levels and breast cancer status was detected at two cut-points evaluated.

Conclusions

Measurement of serum Amphiregulin levels lacks the necessary sensitivity and specificity for breast cancer screening in the general population.

【 授权许可】

   
2013 Peterson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Shoyab M, McDonald VL, Bradley JG, Todaro GJ: Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 1988, 85:6528-6532.
• [2]Martinez-Lacaci I, Saceda M, Plowman GD, Johnson GR, Normanno N, Salomon DS, Dickson RB: Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology 1995, 136:3983-3992.
• [3]Kenny PA, Bissell MJ: Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007, 117:337-345.
• [4]Kenny PA: Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opin Ther Targets 2007, 11:1287-1298.
• [5]Meany DL, Sokoll LJ, Chan DW: Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn 2009, 3:597-605.
• [6]Peterson EA, Shabbeer S, Kenny PA: Normal range of serum Amphiregulin in healthy adult human females. Clin Biochem 2012, 45:460-463.